Notch and Nonalcoholic Fatty Liver and Fibrosis
Coverage in NEJM

Obesity-induced fatty liver, or non-alcoholic fatty liver disease (NAFLD), is the most common form of liver disease in the United States. It ranges in severity from a simple pre-disease state to liver fibrosis, which is the primary determinant of mortality in NAFLD patients. There are no approved pharmacologic options—liver transplantation is the only clinical recourse—a conundrum as obesity prevalence continues to grow and organs are already limited. What follows is an article (see below) that recently appeared in the New England Journal of Medicine on research coming out of the laboratory of Utpal Pajvani, MD, PhD, at the Naomi Berrie Diabetes Center on a developmental pathway called Notch and how the inhibition of Notch signaling may be a novel therapeutic target for the treatment of NAFLD.